Dr Lentzsch on Results for Linvoseltamab in Heavily Pretreated R/R Myeloma

Suzanne Lentzsch, MD, PhD, professor of medicine, director, Multiple Myeloma and Amyloidosis Program, Columbia University Herbert Irving Comprehensive Cancer Center, discusses the data from the phase 1/2 LINKER-MM1 study (NCT03761108) evaluating linvoseltamab in patients with relapsed/refractory multiple myeloma.

Results presented at the 2024 EHA Congress showed that at a median follow-up of 14.3 months, linvoseltamab demonstrated significant efficacy in inducing deep and durable responses in patients with relapsed/refractory multiple myeloma, including those in high-risk subgroups.

The study included 117 patients who received a median of 5 prior lines of treatment (range, 2-16). The median age was 70 years (range, 37-91), and 26.5% of patients were at least 75 years of age. Additionally, 39.3% of patients had had high-risk cytogenetics.

Data showed that the overall response rate (ORR) was 71%, including 50% of patients achieving a complete response (CR) or better. The stringent CR and CR rates were 44.4% and 5.1%, respectively. Additionally, 93% of patients who experienced a CR or better were minimal residual disease (MRD) negative (n = 26/28). The ORR was consistent across prespecified subgroups, including those with baseline extramedullary plasmacytomas and paramedullary disease (n = 36; ORR, 58%), those who were at least 75 years of age (n = 31; 71%), those who were Black (n = 20; 85%), and those with high-risk cytogenetics (n = 46; 67%).

Moreover, Lentzsch notes that linvoseltamab induced deep and durable responses in high-risk subgroups. For patients at least 75 years of age, the ORR was 71% with a CR or better rate of 54.8%. In patients with a high-risk cytogenetics (n = 46), the ORR was 67% with a CR or better rate of 47.8%. Patients with baseline extramedullary plasmacytomas and paramedullary plasmacytomas (n = 36) had an ORR of 58% and a CR or better rate of 27.8%. For patients who were Black (n = 20), the ORR was 85% with a CR or better rate of 45.0%.

Lentzsch emphasizes that these response rates were observed in a heavily pretreated population, particularly amongst the high-risk subgroups. The findings underscore the potential of linvoseltamab as a treatment option for patients with relapsed/refractory multiple myeloma, warranting further investigations to confirm these results and explore long-term outcomes, Lentzsch concludes.